Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Korosho Preparing GL on Biosimilars
April 28, 2008
- Patient Participation Important in Schizophrenia Treatment
April 28, 2008
- REGULATORY NEWS IN BRIEF
April 28, 2008
- Lower Respiratory Tract Treatment Important in Elderly Asthma Patients
April 28, 2008
- Generic Makers Permitted to Use Original Makers' ADR Data without Permission
April 28, 2008
- Half of Hepatitis C Patients who Stop IFN Treatment Do so Because of Cost
April 28, 2008
- 70% of Doctors Permit Substitution for Oral Vitamins
April 28, 2008
- Janssen to Launch 4 New Products per Year
April 28, 2008
- Will Generics Take Off? (1)
April 28, 2008
- Takeda Bio Development Center to Apply for 2 Products by 2010
April 28, 2008
- GENERICS NEWS IN BRIEF
April 28, 2008
- Sanofi-aventis Starts Manufacturing Plavix in Japan
April 28, 2008
- Eisai to Conduct More Collaborative Multinational Clinical Trials
April 28, 2008
- NEW PRODUCTS
April 28, 2008
- Ono to Place Top Priority on Development in US
April 28, 2008
- Ain Pharmaciez to Negotiate Price for Each Product
April 28, 2008
- AZ to Stop JUPITER Study Due to Unequivocal Evidence of Benefits
April 28, 2008
- BUSINESS NEWS IN BRIEF
April 28, 2008
- Prof. Yamanaka Comments on Bayer Yakuhin Team's Reported Achievements with Human iPS Cells
April 28, 2008
- Korosho Officially Approves 22 New Drugs
April 28, 2008
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…